Volume 23, Number 8—August 2017
Research Letter
mcr-1 and blaKPC-3 in Escherichia coli Sequence Type 744 after Meropenem and Colistin Therapy, Portugal
Marta Tacão
, Rafael dos Santos Tavares, Pedro Teixeira, Inês Roxo, Elmano Ramalheira, Sónia Ferreira, and Isabel Henriques
, Rafael dos Santos Tavares, Pedro Teixeira, Inês Roxo, Elmano Ramalheira, Sónia Ferreira, and Isabel Henriques
Table
MIC of antibacterial drugs for Klebsiella pneumoniae Kp81, Escherichia coli Ec36, transconjugant E. coli J53::mcr-1, and recipient strain E. coli J53 *
| Drug |
MIC, mg/L (susceptibility) | |||
|---|---|---|---|---|
| K. pneumoniae Kp81 |
E. coli Ec 36† |
E. coli J53::mcr-1 |
E. coli J53 |
|
| Amikacin | ≥64 (R) | 16 (R) | ND | ND |
| Aztreonam | ≥64 (R) | ≥64 (R) | ND | ND |
| Cefepime | ≥64 (R) | 2 (I) | ND | ND |
| Ceftazidime | ≥64 (R) | ≥64 (R) | ND | ND |
| Ciprofloxacin | ≥4 (R) | ≥4 (R) | ND | ND |
| Colistin | ≤0.5 (S) | 8 (R) | 4 (R) | 0.5 (S) |
| Gentamicin | ≥16 (R) | ≥16 (R) | ND | ND |
| Imipenem | ≥16 (R) | ≥16 (R) | ≤0.25 (S) | ≤0.25 (S) |
| Meropenem | ≥16 (R) | ≥16 (R) | ≤0.25 (S) | ≤0.25 (S) |
| Piperacillin | ≥128 (R) | ≥128 (R) | ND | ND |
| Piperacillin/tazobactam | ≥128 (R) | ≥128 (R) | ND | ND |
| Ticarcillin | ≥128 (R) | ≥128 (R) | ND | ND |
| Ticarcillin/clavulanic acid | ≥128 (R) | ≥128 (R) | ND | ND |
| Tigecycline | 1.5 (S) | 1 (S) | 0.25 (S) | 0.25 (S) |
| Tobramycin | ≥16 (R) | ≥16 (R) | ND | ND |
| Trimethoprim/sulfamethoxazole | ≥320 (R) | ≥320 (R) | ND | ND |
*MICs were determined by using VITEK2 system AST-N222 (bioMérieux, Marcy-l'Étoile, France), except colistin, for which MICRONAUT MIC-strip (BioConnections, Knypersley, UK) was used, and interpreted according to the European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org). Shaded rows indicate antibacterial drugs tested for efficacy against each of the 4 organisms. ND, not determined; R, resistant; S, susceptible.
†Strain isolated from the patient in this study.
Page created: July 17, 2017
Page updated: July 17, 2017
Page reviewed: July 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.